Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Dermatologic 1Breast 1

Conditions

Sarcoma 1Mycosis Fungoides 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 10Gemcitabine 8Cyclophosphamide 7Filgrastim 5Docetaxel 5Carboplatin 5Trastuzumab 4Surveys and Questionnaires 4Nivolumab 4Doxorubicin 4Cisplatin 4poly ICLC 3pazopanib 3atezolizumab 3aldesleukin 3Taxes 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Ipilimumab 3Injections 3Drug Therapy 3Cetuximab 3Capecitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3spartalizumab 2palbociclib 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × TTI-621 × Breast × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡